Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide

被引：0
|
作者：
Jonas Kildegaard
Stephen T. Buckley
Rasmus H. Nielsen
Gro K. Povlsen
Torben Seested
Ulla Ribel
Helle B. Olsen
Svend Ludvigsen
Claus B. Jeppesen
Hanne H. F. Refsgaard
Kristian M. Bendtsen
Niels R. Kristensen
Susanne Hostrup
Jeppe Sturis
机构：
[1] Novo Nordisk A/S,
来源：
Pharmaceutical Research | 2019年 / 36卷
关键词：
absorption; fast-acting insulin aspart; niacinamide; oligomerization; vasodilation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
    Kildegaard, Jonas
    Buckley, Stephen T.
    Nielsen, Rasmus H.
    Povlsen, Gro K.
    Seested, Torben
    Ribel, Ulla
    Olsen, Helle B.
    Ludvigsen, Svend
    Jeppesen, Claus B.
    Refsgaard, Hanne H. F.
    Bendtsen, Kristian M.
    Kristensen, Niels R.
    Hostrup, Susanne
    Sturis, Jeppe
    PHARMACEUTICAL RESEARCH, 2019, 36 (03)
  • [2] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Marc Evans
    Mathew Wilkinson
    Angeliki Giannpolou
    Diabetes Therapy, 2019, 10 : 1793 - 1800
  • [3] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Evans, Marc
    Wilkinson, Mathew
    Giannpolou, Angeliki
    DIABETES THERAPY, 2019, 10 (05) : 1793 - 1800
  • [4] A trial of fast-acting aspart insulin (FIASP) in insulin pumps
    Khan, A. K.
    Weston, P. W. Philip
    Brake, J. B.
    Lamen, L. L.
    Ndebu, J. N.
    Ord, C. O.
    DIABETIC MEDICINE, 2023, 40
  • [5] Use of fast-acting insulin aspart in insulin pump therapy in clinical practice
    Evans, Mark
    Ceriello, Antonio
    Danne, Thomas
    De Block, Christophe
    DeVries, J. Hans
    Lind, Marcus
    Mathieu, Chantal
    Norgaard, Kirsten
    Renard, Eric
    Wilmot, Emma G.
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2039 - 2047
  • [6] Fast-Acting Insulin Aspart Use with the MiniMedTM 670G System
    Hsu, Liana
    Buckingham, Bruce
    Basina, Marina
    Ekhlaspour, Laya
    von Eyben, Rie
    Wang, Justin
    Lal, Rayhan A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (01) : 1 - 7
  • [7] FAST-ACTING INSULIN ASPART AT HIGH DOSES IN INDIVIDUALS WITH TYPE 2 DIABETES
    Bowering, K.
    Harvey, J.
    Kolaczynski, J.
    Snyder, J.
    Bode, B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A133 - A133
  • [8] Fast-Acting Insulin aspart (faster aspart) - Clinical Data on Application in Type 1 and 2 Diabetes
    Jaeckel, E.
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (06): : 313 - 319
  • [9] Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart
    Pieber, T. R.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    DIABETOLOGIA, 2017, 60 : S315 - S315
  • [10] Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: Comparison with insulin aspart in onset 1
    Twigg, Stephen
    Mathieu, Chantal
    Bode, Bruce
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 63 - 63
12345